{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:27:53Z","timestamp":1773678473367,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","award":["1342110"],"award-info":[{"award-number":["1342110"]}],"id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40272-025-00735-0","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:50:02Z","timestamp":1768999802000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Toward Optimal Treatment Outcomes in New-Onset Polyarticular-Course Juvenile Idiopathic Arthritis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-0115","authenticated-orcid":false,"given":"Adam Seth","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-3390","authenticated-orcid":false,"given":"Yukiko","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"2","key":"735_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"key":"735_CR2","volume-title":"Textbook of pediatric rheumatology","year":"2021","unstructured":"Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, Mellins ED, Fuhlbrigge RC, editors. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier; 2021.","edition":"8"},{"issue":"6","key":"735_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/annrheumdis-2014-207164","volume":"75","author":"J Guzman","year":"2016","unstructured":"Guzman J, Oen K, Huber AM, et al. The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Ann Rheum Dis. 2016;75(6):1092\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207164.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"735_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/rheumatology\/41.12.1428","volume":"41","author":"JC Packham","year":"2002","unstructured":"Packham JC, Hall MA. Long\u2010term follow\u2010up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology. 2002;41(12):1428\u201335. https:\/\/doi.org\/10.1093\/rheumatology\/41.12.1428.","journal-title":"Rheumatology"},{"issue":"9","key":"735_CR5","first-page":"1989","volume":"29","author":"K Oen","year":"2002","unstructured":"Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29(9):1989\u201399.","journal-title":"J Rheumatol"},{"issue":"11","key":"735_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.41390","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Schanberg LE, Kimura Y, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72(11):1945\u201351. https:\/\/doi.org\/10.1002\/art.41390.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"735_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/acr.22259","volume":"66","author":"S Ringold","year":"2014","unstructured":"Ringold S, Weiss PF, Colbert RA, et al. Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2014;66(7):1063\u201372. https:\/\/doi.org\/10.1002\/acr.22259.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"22","key":"735_CR8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586\u201393. https:\/\/doi.org\/10.1056\/NEJM200011303432201.","journal-title":"N Engl J Med"},{"issue":"2","key":"735_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.10083","volume":"46","author":"RBM Landew\u00e9","year":"2002","unstructured":"Landew\u00e9 RBM, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347\u201356. https:\/\/doi.org\/10.1002\/art.10083.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"735_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/art.10308","volume":"46","author":"MC Genovese","year":"2002","unstructured":"Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443\u201350. https:\/\/doi.org\/10.1002\/art.10308.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"735_CR11","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YPM Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381\u201390. https:\/\/doi.org\/10.1002\/art.21405.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"735_CR12","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112\u201324. https:\/\/doi.org\/10.1002\/art.40851.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"735_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257\u201369. https:\/\/doi.org\/10.1038\/s41584-021-00590-6.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"735_CR14","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/art.38615","volume":"66","author":"PA Nigrovic","year":"2014","unstructured":"Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405\u201313. https:\/\/doi.org\/10.1002\/art.38615.","journal-title":"Arthritis Rheumatol"},{"key":"735_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00768-6","volume":"20","author":"T Beukelman","year":"2022","unstructured":"Beukelman T, Tomlinson G, Nigrovic PA, et al. First-line options for systemic juvenile idiopathic arthritis treatment: an observational study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Pediatr Rheumatol Online J. 2022;20:113. https:\/\/doi.org\/10.1186\/s12969-022-00768-6.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"735_CR16","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/art.38296","volume":"66","author":"SJ Vastert","year":"2014","unstructured":"Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034\u201343. https:\/\/doi.org\/10.1002\/art.38296.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"735_CR17","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/ard.2010.143347","volume":"70","author":"P Tynj\u00e4l\u00e4","year":"2011","unstructured":"Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605\u201312. https:\/\/doi.org\/10.1136\/ard.2010.143347.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"735_CR18","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012\u201321. https:\/\/doi.org\/10.1002\/art.34343.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"735_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.131503","volume":"41","author":"CA Wallace","year":"2014","unstructured":"Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41(6):1163\u201370. https:\/\/doi.org\/10.3899\/jrheum.131503.","journal-title":"J Rheumatol"},{"issue":"10","key":"735_CR20","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/art.41888","volume":"73","author":"Y Kimura","year":"2021","unstructured":"Kimura Y, Schanberg LE, Tomlinson GA, et al. Optimizing the start time of biologics in polyarticular juvenile idiopathic arthritis: a comparative effectiveness study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis Rheumatol. 2021;73(10):1898\u2013909. https:\/\/doi.org\/10.1002\/art.41888.","journal-title":"Arthritis Rheumatol"},{"key":"735_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/art.43216","author":"S Ringold","year":"2025","unstructured":"Ringold S, Ong MS, Tomlinson G, et al. Three-year outcomes and latent class trajectory analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans study. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43216.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"735_CR22","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/acr.20497","volume":"63","author":"CA Wallace","year":"2011","unstructured":"Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929\u201336. https:\/\/doi.org\/10.1002\/acr.20497.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"735_CR23","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/art.41879","volume":"73","author":"C Trincianti","year":"2021","unstructured":"Trincianti C, Van Dijkhuizen EHP, Alongi A, et al. Definition and validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score\u00a0cutoffs for disease activity states in juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(11):1966\u201375. https:\/\/doi.org\/10.1002\/art.41879.","journal-title":"Arthritis Rheumatol"},{"key":"735_CR24","doi-asserted-by":"publisher","unstructured":"de Jonge JB, de Roock S, Schonenberg-Meinema D, et al. Effect of time to start of biologic therapy on treatment response in childhood arthritis: results from the UCAN CAN-DU study. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43401.","DOI":"10.1002\/art.43401"},{"issue":"1","key":"735_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001091","volume":"6","author":"B Huang","year":"2020","unstructured":"Huang B, Qiu T, Chen C, et al. Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open. 2020;6(1):e001091. https:\/\/doi.org\/10.1136\/rmdopen-2019-001091.","journal-title":"RMD Open"},{"issue":"7","key":"735_CR26","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139. https:\/\/doi.org\/10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"735_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-020-00488-9","volume":"19","author":"E Alexeeva","year":"2021","unstructured":"Alexeeva E, Horneff G, Dvoryakovskaya T, et al. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial. Pediatr Rheumatol. 2021;19(1):5. https:\/\/doi.org\/10.1186\/s12969-020-00488-9.","journal-title":"Pediatr Rheumatol"},{"issue":"9","key":"735_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.40509","volume":"70","author":"DJ Lovell","year":"2018","unstructured":"Lovell DJ, Johnson AL, Huang B, et al. Risk, timing, and predictors of disease flare after discontinuation of anti-tumor necrosis factor therapy in\u00a0children with polyarticular forms of juvenile idiopathic\u00a0arthritis with clinically inactive disease. Arthritis Rheumatol. 2018;70(9):1508\u201318. https:\/\/doi.org\/10.1002\/art.40509.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"735_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-022-00739-x","volume":"20","author":"M Burrone","year":"2022","unstructured":"Burrone M, Mazzoni M, Naddei R, et al. Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the \u201ccomparison of STep-up and step-down therapeutic strategies in childhood ARthritiS\u201d (STARS) trial. Pediatr Rheumatol Online J. 2022;20(1):80. https:\/\/doi.org\/10.1186\/s12969-022-00739-x.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"6","key":"735_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res. 2019;71(6):717\u201334. https:\/\/doi.org\/10.1002\/acr.23870.","journal-title":"Arthritis Care Res"},{"issue":"11","key":"735_CR31","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/acr.24727","volume":"74","author":"CK Correll","year":"2022","unstructured":"Correll CK, Shrader P, Dennos A, et al. Effectiveness and safety of high-dose biologics in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance. Arthritis Care Res (Hoboken). 2022;74(11):1770\u20139. https:\/\/doi.org\/10.1002\/acr.24727.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"735_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.rdc.2021.07.012","volume":"47","author":"NJ Shiff","year":"2021","unstructured":"Shiff NJ, Beukelman T. Pharmacosurveillance in juvenile idiopathic arthritis. Rheum Dis Clin North Am. 2021;47(4):643\u201353. https:\/\/doi.org\/10.1016\/j.rdc.2021.07.012.","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"735_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13075-020-02167-2","volume":"22","author":"G Giancane","year":"2020","unstructured":"Giancane G, Swart JF, Castagnola E, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22(1):71. https:\/\/doi.org\/10.1186\/s13075-020-02167-2.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"735_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"issue":"3","key":"735_CR35","first-page":"579","volume":"30","author":"F Fantini","year":"2003","unstructured":"Fantini F, Gerloni V, Gattinara M, Cimaz R, Arnoldi C, Lupi E. Remission in juvenile chronic arthritis: a cohort study of 683 consecutive cases with a mean 10 year followup. J Rheumatol. 2003;30(3):579\u201384.","journal-title":"J Rheumatol"},{"key":"735_CR36","unstructured":"Flat\u00f8 B, Lien G, Smerdel A, et al. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. J Rheumatol. 2003;30(2):386\u201393."},{"issue":"3","key":"735_CR37","first-page":"492","volume":"26","author":"BE Gilliam","year":"2008","unstructured":"Gilliam BE, Chauhan AK, Low JM, Moore TL. Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. Clin Exp Rheumatol. 2008;26(3):492\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"735_CR38","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1002\/art.11337","volume":"48","author":"S Magni-Manzoni","year":"2003","unstructured":"Magni-Manzoni S, Rossi F, Pistorio A, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum. 2003;48(12):3509\u201317. https:\/\/doi.org\/10.1002\/art.11337.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"735_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3899\/jrheum.160197","volume":"44","author":"J Guzman","year":"2017","unstructured":"Guzman J, Henrey A, Loughin T, et al. Predicting which children with juvenile idiopathic arthritis will have a severe disease course: results from the ReACCh-Out cohort. J Rheumatol. 2017;44(2):230\u201340. https:\/\/doi.org\/10.3899\/jrheum.160197.","journal-title":"J Rheumatol"},{"key":"735_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004317","author":"M Glerup","year":"2024","unstructured":"Glerup M, Kessel C, Foell D, et al. Inflammatory biomarkers predicting long-term remission and active disease in juvenile idiopathic arthritis: a population-based study of the Nordic JIA cohort. RMD Open. 2024. https:\/\/doi.org\/10.1136\/rmdopen-2024-004317.","journal-title":"RMD Open"},{"issue":"9","key":"735_CR41","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1093\/rheumatology\/kez615","volume":"59","author":"E Rezaei","year":"2020","unstructured":"Rezaei E, Hogan D, Trost B, et al. Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2020;59(9):2402\u201311. https:\/\/doi.org\/10.1093\/rheumatology\/kez615.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"735_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/children12060741","volume":"12","author":"AI Rebollo-Gim\u00e9nez","year":"2025","unstructured":"Rebollo-Gim\u00e9nez AI, Ridella F, Orsi SM, et al. Forecasting achievement of inactive disease in juvenile idiopathic arthritis with artificial intelligence. Children. 2025;12(6):741. https:\/\/doi.org\/10.3390\/children12060741.","journal-title":"Children"},{"issue":"5","key":"735_CR43","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3899\/jrheum.210709","volume":"49","author":"T El Tal","year":"2022","unstructured":"El Tal T, Ryan ME, Feldman BM, et al. Consensus approach to a treat-to-target strategy in juvenile idiopathic arthritis care: report from the 2020 PR-COIN Consensus Conference. J Rheumatol. 2022;49(5):497\u2013503. https:\/\/doi.org\/10.3899\/jrheum.210709.","journal-title":"J Rheumatol"},{"issue":"6","key":"735_CR44","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213030.","journal-title":"Ann Rheum Dis"},{"issue":"9430","key":"735_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(04)16676-2","volume":"364","author":"C Grigor","year":"2004","unstructured":"Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(04)16676-2.","journal-title":"Lancet"},{"issue":"9","key":"735_CR46","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1136\/ard.2004.030924","volume":"64","author":"J Fransen","year":"2005","unstructured":"Fransen J, Moens HB, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis. 2005;64(9):1294\u20138. https:\/\/doi.org\/10.1136\/ard.2004.030924.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"735_CR47","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3899\/jrheum.190268","volume":"47","author":"L Buckley","year":"2020","unstructured":"Buckley L, Ware E, Kreher G, Wiater L, Mehta J, Burnham JM. Outcome monitoring and clinical decision support in polyarticular juvenile idiopathic arthritis. J Rheumatol. 2020;47(2):273\u201381. https:\/\/doi.org\/10.3899\/jrheum.190268.","journal-title":"J Rheumatol"},{"issue":"1","key":"735_CR48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","volume":"78","author":"P Hissink Muller","year":"2019","unstructured":"Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78(1):51\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213902.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"735_CR49","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","volume":"79","author":"A Klein","year":"2020","unstructured":"Klein A, Minden K, Hospach A, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216843.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00735-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00735-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:13:11Z","timestamp":1773673991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00735-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00735-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by a Rheumatology Research Foundation Scientist Development Award [1342110 to A.S.M.].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.S.M: None; Y.K.: Y.K. receives salary support from the Childhood Arthritis and Rheumatology Research Association (CARRA), royalties from UptoDate","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A.S.M. and Y.K. both contributed to the literature review, initial drafting, and editing and revision of this manuscript. All authors have read and approved the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}